



Fourth Quarter & Full Year 2023 Financial Results

February 29, 2024



Disclaimer

Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them.

Trademarks and Service Marks

The Certara design logo, "Certara," and our other registered or common law trademarks, service marks or trade names appearing in this presentation are our property. Solely for convenience, our trademarks, tradenames, and service marks referred to in this presentation appear without the registered mark or trademark symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights to these trademarks, tradenames, and service marks. This presentation contains additional trademarks, tradenames, and service marks of other companies that are the property of their respective owners. We do not intend our use or display of other companies' trademarks, trade names or service marks to imply relationships with, or endorsement or sponsorship of us by, these other companies.

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, that reflect the Company's current views with respect to, among other things, the Company's operations and financial performance. Forward-looking statements include words such as "anticipate," "expect," "suggest," "plan," "believe," "intend," "project," "forecast," "expectations, including descriptions of our business plan and strategies. These statements often include words such as "anticipate," "suggest," "plan," "believe," "intend," "project," "forecast," "expectations, plans and assumptions, while," and other similar expressions. We base these forward-looking statements or projections of nur current expectations of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at the time. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the Company's ability to compete within its market; any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery; changes or delays in relevant government regulation; increasing competition, regulation and other cost pressures within the pharmaceutical and biotechnology industries; economic conditions, including inflation, recession, currency exchange flucture development in the fractors detailed under the captions or disruptions or dela

Non-GAAP Financial Information

This presentation contains "non-GAAP measures" that are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles ("GAAP"). Specifically, we make use of the non-GAAP financial measures adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted diluted earnings per share ("EPS"), and constant currency ("CC") revenue, which are not recognized terms under GAAP and should not be considered as alternatives to net income (loss), GAAP EPS, or GAAP revenue as measures of financial performance or cash provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. These non-GAAP measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

Adjusted EBITDA represents net income (loss) excluding interest expense, provision (benefit) for income taxes, depreciation and amortization expense, intangible asset amortization, equity-based compensation expense, acquisition and integration expense and other items not indicative of our ongoing operating performance. Adjusted EBITDA margin represents adjusted EBITDA divided by revenue. Adjusted net income and adjusted diluted EPS exclude the effect of the same items noted above with respect to adjusted EBITDA from GAAP net income (loss) and GAAP EPS, respectively, as well as adjust the provision for income taxes for such charges. CC revenue excludes the effects of foreign currency exchange rate fluctuations by assuming constant foreign currency exchange rates used for translation. Current periods revenue reported in currencies other than U.S. dollars are converted into U.S. dollars at the average exchange rates in effect for the comparable prior periods. You should refer to the appendix at the end of this document for a reconciliation of these non-GAAP measures in specific periods to their most directly comparable financial measures calculated and presented in accordance with GAAP for those periods.

Management uses various financial metrics, including total revenues, income from operations, net income, CC revenue and certain non-GAAP measures, including those discussed above, to measure and assess the performance of the Company's business, to evaluate the effectiveness of its business strategies, to make budgeting decisions, to make certain compensation decisions, and to compare the Company's performance against that of other peer companies using similar measures. In addition, management believes these metrics provide useful measures for period-to-period comparisons of the Company's business, as they remove the effect of certain non-cash expenses and other items not indicative of its ongoing operating performance. Management believes that these metrics are helpful to investors, analysts, and other interested parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, these measures are frequently used by analysts, investors, and other interested parties to evaluate and assess performance. In addition, our business has operations outside the United States that are conducted in local currencies. As a result, the comparability of the financial results reported in U.S. dollars is affected by changes in foreign currency exchange rates. We use CC revenue to evaluate the underlying performance of the business, and we believe it is helpful for investors to present operating results on a comparable basis period over period to evaluate its underlying performance. In evaluating adjusted EBITDA, adjusted net income (loss), adjusted diluted EPS, and CC revenue, you should be aware that in the future the Company may incur expenses similar to those eliminated in this presentation and this presentation should not be construed as an inference that future results will be unaffected by unusual items.

CFRTARA

Certara at a Glance

BUSINESS ⁽¹⁾	END-TO-END PLATFORM		FY 2023 FINANCIALS				
Ţ		ALL					
20+ Year History of innovation	 Software Biosimulation Regulatory & compliance Market access Drug discovery & development with biosimulation Regulatory science Market access 	osimulation ~2,400 Customers across 66 countries					
~1,400 Employees							
430 +with Ph.D.s, Pharm.D.s and M.D.s	• Drug discovery & development with	10+ Year Average tenure for top 30 customers	Net Income (\$55.4M) ⁽⁵⁾ PY \$14.7M				
			\$123.1M Reported Adjusted				
20 Acquisitions	Market access	389 customers with ACV > \$100,000	EBITDA ⁽⁶⁾ PY \$120.2M				
Track record of accretive, complementary acquisitions		63 customers with ACV > \$1M	35% Adjusted EBITDA Margin ⁽⁶⁾				

(1) As of 12/31/2023

(2) Market research reports from Grand View and SpendEdge; as of 2024

(3) Customer data as of 12/31/2023

(4) See Appendix for reconciliation of GAAP revenue to constant currency (non-GAAP revenue)

(5) Net Income includes a \$47.0 million goodwill impairment expense in the third quarter of 2023 related to the Regulatory business; Includes \$12.8 million increase in fair value related to remeasurement of contingent considerations primarily related to Vyasa Analytics due to performance of the

business

(6) See Appendix for reconciliation of net income (loss) to adjusted EBITDA



Financial Highlights

Full Year 2023





(1) See Appendix for reconciliation of GAAP revenue to constant currency (non-GAAP revenue)

(2) Net Income includes a \$47.0 million goodwill impairment expense in the third quarter of 2023 related to the Regulatory business and Includes a \$12.8 million increase in fair value related to remeasurement of contingent considerations primarily related to Vyasa Analytics due to performance of the business

CERTARA

(3) YoY growth cannot be represented by a percentage, due to negative current year Net Income


(4) See Appendix for reconciliation of net income (loss) to adjusted EBITDA

(5) See Appendix for reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Sha

Financial Highlights

Fourth Quarter 2023





(1) See Appendix for reconciliation of GAAP revenue to constant currency (non-GAAP revenue)

(2) Net Income Includes a \$12.8 million increase in fair value related to remeasurement of contingent considerations primarily related to Vyasa Analytics due to performance of the business

(3) YoY growth cannot be represented by a percentage, due to negative current year Net Income

(4) See Appendix for reconciliation of net income (loss) to adjusted EBITDA

(5) See Appendix for reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share

© Copyright 2024 Certara, L.P. All rights reserved.

CERTARA

Full Year 2023 Results - Revenue



Certara reported 6% constant currency⁽¹⁾ revenue growth

(1) See Appendix for reconciliation of GAAP revenue to constant currency (non-GAAP revenue)

© Copyright 2024 Certara, L.P. All rights reserved.



4Q 2023 Results - Revenue




Certara reported 1% constant currency⁽¹⁾ revenue growth

(1) See Appendix for reconciliation of GAAP revenue to constant currency (non-GAAP revenue)




4Q and TTM 2023 Results - Net Bookings




Trailing twelve months bookings are highly correlated with revenue and drive strong visibility

CERTARA

Historical TTM Book to Bill




Book to bill provides forward visibility into revenue growth





4Q and Full Year 2023 Results – Adjusted EBITDA



(1) See Appendix for a reconciliation net income (loss) to adjusted EBITDA



4Q23 Business Updates

Key Takeaways from Fourth Quarter:





Improved Execution Across Commercial Organization

- Bookings strength in both software and services, driven by improved execution and go-to-market strategy
- New commercial infrastructure creates additional cross-selling opportunities, boosting win rates across business

Bolt-On Acquisitions Expand Offering

- Acquisition of Applied Biomath gives Certara the largest QSP services group in the drug development industry
- Formedix combines with Pinnacle21 to create end-to-end solution for clinical trial data management

Investing in Key Growth Initiatives in 2024

- Investing in salesforce to improve go-tomarket strategy, expansion of the customer base and key account management
- Accelerating R&D to new develop additional biosimulation models and further incorporate AI/ML into software





4Q23 Bookings YoY Trends – Pharma/Biotech Customers


Tier ⁽¹⁾	Software Bookings	Services Bookings
I	Growth below historical company averages, mainly due to timing of renewals	Declined year over year due to large bookings in Q4'22, but improved sequentially
П	Strongest area of growth in software bookings, driven by further adoption of biosimulation	Growth driven by expansion to new customers, increase in average deal size
Ш	Growth in-line with historical company averages, driven by expansion to new customers	Declined as expected due to cautious customer spending, large bookings in Q4'22

Software bookings driven by expansion of biosimulation to new customers Services bookings driven by improving commercial execution

(1) Certara's Pharma Customer tiering is defined as follows: Tier 1 represents Biopharma customers with more than \$5B USD in Revenue, Tier 2 represents companies with revenue between \$100M and \$4.99B USD in revenue, Tier 3 represents customers with revenues less than 100M, including non-revenue generating companies.



2024 Outlook



This financial guidance is provided as of February 29, 2024, and its inclusion in this presentation should not be construed as continued affirmation of such guidance beyond that date.

(1) We have not reconciled the adjusted EBITDA and adjusted diluted EPS forward-looking guidance above to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to costs related to acquisitions, financings, and employee stock compensation programs, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.

Key Assumptions 2024 Guidance

- Reported revenue growth of 9-13%
- Full year adjusted EBITDA expected to grow YoY
- Fully diluted shares expected to be in the range of 160-162
- Tax rate expected to be 25-30%





Appendix



Reconciliation of Net Income (Loss) to Adjusted EBITDA

		2022 20 (in thousands) \$ \$ 9,174 \$ \$ 9,174 \$ () 5,445 () () () 5,445 () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()		Twelve Mor Decem			
	2023		2022		2023		2022
			(in tho	usar	nds)		
Net income (loss)(a)	\$ (12,456)	\$	9,174	\$	(55,357)	\$	14,731
Interest expense(a)	5,870		5,445		22,916		17,773
Interest income(a)	(2,889)		(947)		(9,317)		(1,294)
(Benefit from) Provision for income taxes(a)	72		(5,449)		214		4,024
Depreciation and amortization expense(a)	413		410		1,552		1,731
Intangible asset amortization(a)	14,420		12,732		54,519		50,739
Currency (gain) loss(a)	803		2,473		638		(3,166)
Equity-based compensation expense(b)	7,502		6,527		28,300		30,345
Change in fair value of contingent consideration(d)	12,802		—		24,118		
Goodwill impairment expense(e)			—		46,984		—
Acquisition-related expenses(f)	2,788		902		6,064		2,233
Integration expense(g)	(69)				121		
Transaction-related expenses(h)			412				1,136
Severance expenses(i)			(69)				653
Reorganization expense(j)	58		—		1,660		
Loss on disposal of fixed assets(k)	36		113		65		169
Executive recruiting expense(l)	235		139		631		139
First-year Sarbanes-Oxley implementation costs(m)							961
Adjusted EBITDA	\$ 29,585	\$	31,862	\$	123,108	\$	120,174



Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)

	Three Months Ended December 31,				r	Twelve Mo Decem	nths Ended ber 31,		
		2023	2	022		2023		2022	
				(in tho	usano	ds)			
Net income (loss) (a)	\$	(12,456)	\$	9,174	\$	(55,357)	\$	14,731	
Currency (gain) loss(a)		803		2,473		638		(3,166)	
Equity-based compensation expense(b)		7,502		6,527		28,300		30,345	
Amortization of acquisition-related intangible assets(c)		11,946		10,922		45,838		43,822	
Change in fair value of contingent consideration(d)		12,802				24,118		—	
Goodwill impairment expense(e)						46,984		_	
Acquisition-related expenses(f)		2,788		902		6,064		2,233	
Integration expense(g)		(69)				121		_	
Transaction-related expenses(h)				412				1,136	
Severance expenses(i)				(69)		_		653	
Reorganization expense(j)		58				1,660		—	
Loss on disposal of fixed assets(k)		36		113		65		169	
Executive recruiting expense(l)		235		139		631		139	
First-year Sarbanes-Oxley implementation costs(m)								961	
Income tax expense impact of adjustments(n)		(9,372)		(5,397)		(30,041)		(17,633)	
Adjusted net income	\$	14,273	\$	25,196	\$	69,021	\$	73,390	



Reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share

	Three Months Ended December 31,				r	Twelve Mon Decem	nths Ended ber 31,		
	2	2023		2022		2023		2022	
		(In th	ousan	ds except sh	are a	nd per share	e data	ı)	
Diluted earnings per share(a)	\$	(0.08)	\$	0.06	\$	(0.35)	\$	0.09	
Currency (gain) loss(a)		0.01		0.02				(0.02)	
Equity-based compensation expense(b)		0.05		0.04		0.18		0.19	
Amortization of acquisition-related intangible assets(c)		0.07		0.06		0.29		0.28	
Change in fair value of contingent consideration(d)		0.08				0.15		—	
Goodwill impairment expense(e)						0.30		_	
Acquisition-related expenses(f)		0.02		0.01		0.04		0.01	
Integration expense(g)								_	
Transaction-related expenses(h)								0.01	
Severance expenses(i)								_	
Reorganization expense(j)		—				0.01			
Loss on disposal of fixed assets(k)								_	
Executive recruiting expense(l)		—							
First-year Sarbanes-Oxley implementation costs(m)								0.01	
Income tax expense impact of adjustments(n)		(0.06)		(0.03)		(0.19)		(0.11)	
Adjusted Diluted Earnings Per Share	\$	0.09	\$	0.16	\$	0.43	\$	0.46	
Basic weighted average common shares outstanding	159	,430,660	157	7,927,161	15	8,936,251	15	56,876,942	
Effect of potentially dilutive shares outstanding (o)		544,784	1	1,314,056		943,886		2,477,452	
Adjusted diluted weighted average common shares	159	,975,444	159	9,241,217	15	9,880,137	15	59,354,394	



Reconciliation of Revenues to the Revenues Adjusted for Constant Currency

	 Three													
	 2023		2023		2022	\$ Actual		% Actual		\$		%		
	 Actual		СС		Actual					CC	Impact			
	(GAAP)	(n	on-GAAP)		(GAAP)	(GAAP)		(GAAP)		P) (non-GAAP)		(non-GAAP)		
	(in thousands except percentage)													
Revenue														
Software	\$ 33,619	\$	33,161	\$	29,156	\$	4,463		15%	\$	(458)	14%		
Services	54,391		53,975		57,477		(3,086)		-5%		(416)	-6%		
Total Revenue	\$ 88,010	\$	87,136	\$	86,633	\$	1,377		2%	\$	(874)	1%		

		Twelv	ve N	Months E	nde	ed										
	December 31,							Change								
	20	23		2023		2022	Actual Actual				s % \$		\$	%		
	Act	tual		CC		Actual							t			
	(GA	AP)	(n	on-GAAP)		(GAAP)							(non-GAA	P)		
						(in thousa	nds ex	cept percer	tage)							
Revenue																
Software	\$ 13	1,677	\$	131,674	\$	115,466	\$	16,211		14%	\$	(3)	14	1%		
Services	22	2,660		222,574		220,178		2,482		1%		(86)	1	1%		
Total Revenue	\$ 35	4,337	\$	354,248	\$	335,644	\$	18,693		6%	\$	(89)	6	%		

Notes to Reconciliations

(a.) Represents amounts as determined under GAAP.

(b.) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.

(c.) Represents amortization costs associated with acquired intangible assets in connection with business acquisitions.

(d.) Represents expense associated with remeasuring fair value of contingent consideration of business acquisition.

(e.) Represents expense associated with goodwill impairment charge.

(f.) Represents costs associated with mergers and acquisitions and any retention bonuses pursuant to the acquisitions.

(g.) Represents integration costs related to post - acquisition integration activities.

(h.) Represents costs associated with our public offerings that are not capitalized.

(i.) Represents charges for severance provided to former executives.

(j.) Represents expense related to reorganization, including legal entity reorganization and lease abandonment cost associated with the evaluation of our office space footprint.

(k.) Represents the gain/loss related to disposal of fixed assets.

(I.) Represents recruiting and relocation expenses related to hiring senior executives.

(m.) Represents the first-year Sarbanes-Oxley costs for accounting and consulting fees related to the Company's preparation to comply with Section 404 of the Sarbanes-Oxley Act, as well as implementation cost of adopting ASC 842.

(n.) Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction.

(o.) Represents dilutive shares or potentially dilutive shares that were excluded from the Company's GAAP diluted weighted average common shares outstanding because the Company had a reported net loss and therefore including these shares would have been anti-dilutive.





Accelerating Medicines, Together

